672883-68-0

Basic information

• Product Name: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride
• Synonyms: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride
• CAS NO: 672883-68-0
• Molecular Formula: C₁₂H₁₁ClF₂O₃
• Molecular Weight: 276.6637464
• Mol File: 672883-68-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 352.84°C at 760 mmHg
• Flash Point: 144.06°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(672883-68-0)
• EPA Substance Registry System: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(672883-68-0)

Safety Data

• Hazardous Substances Data: 672883-68-0(Hazardous Substances Data)

Usage

General Description

3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride is a chemical compound with the molecular formula C12H10ClF2O3. It is a benzoyl chloride derivative with a cyclopropylMethoxy group at the 3-position and a difluoroMethoxy group at the 4-position. 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride is commonly used in organic synthesis as a reagent for the introduction of the benzoyl group and can be utilized in the preparation of various pharmaceutical and agrochemical compounds. It is important to handle this compound with caution, as it is a reactive and potentially hazardous substance.

InChI:InChI=1/C12H11ClF2O3/c13-11(16)8-3-4-9(18-12(14)15)10(5-8)17-6-7-1-2-7/h3-5,7,12H,1-2,6H2

Upstream product

• 162401-62-9 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 151103-09-2 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 1381886-14-1 4-(benzyloxy)-3-(cyclopropylmethoxy)benzaldehyde 
• 25934-52-5 3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde 

Downstream Products

• 672883-67-9 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2,6-dioxo-hexahydropyridine 
• 672883-84-0 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2-oxohexahydro-pyridine 
• 672883-90-8 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2-oxo-1-phenyl-hexahydropyridine 
• 672883-96-4 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-6-oxo-hexahydropyridine 
• 672884-01-4 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-6-oxo-1-phenyl-hexahydropyridine 
• 162401-32-3 roflumilast 
• 1001909-97-2 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloro-1-pyridin-4-yl)ethanone 

Relevant articles and documents

Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease

Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands fo

A method for preparing raw material for roflumilast and detection method

The invention discloses a preparation method and a detection method of a roflumilast material. The preparation method comprises the following steps: mixing 3-cyclopropyl methoxy group-4-difluoro methoxy group benzoic acid SM-1, thionyl chloride, dimethyl formamide with toluene, and carrying out an acylating chlorination reaction to obtain a midbody 1; mixing 3,5-dichloro-4-aminopyridine SM-2, tetrahydrofuran with potassium tert-butoxide and carrying out a salt forming reaction to obtain tetrahydrofuran solution of a midbody 2; and then mixing the midbody 1 and the midbody 2 with tetrahydrofuran, carrying out amidation to obtain a crude product of roflumilast, and refining the crude product of roflumilast to prepare the roflumilast material. Aiming to overcome the shortage of the prior art, the preparation process of the roflumilast material is optimized, so that the curative effect for treating diseases such as chronic obstructive pulmonary disease (COPD) is more remarkable; and besides, a systematic, complete and effective composition identifying and content measuring method is provided, so that the quality of the medicine can be effectively controlled, and the clinical effect is ensured.

Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses

Depression involving neuroinflammation is one of the most common disabling and life-threatening psychiatric disorders. Phosphodiesterase 4 (PDE4) inhibitors produce potent antidepressant-like and cognition-enhancing effects. However, their clinical utilit